eliquis apixaban logo eliquis apixaban logo eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

Eliquis (Apixaban) Mechanism Of Action

An oral, direct and highly selective factor Xa inhibitor1

ELIQUIS inhibits free and clot-bound factor Xa, and prothrombinase activity.

ELIQUIS has no direct effects on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting factor Xa, ELIQUIS prevents thrombin generation and thrombus development.1

  • Factor Xa is the primary site of amplification in the coagulation cascade2
  • ELIQUIS binds reversibly to Factor Xa1
  • One factor Xa molecule leads to the formation of ~1,000 thrombin molecules2

Adapted from Eriksson et al. 2011.3

Diagnosemethoden

The approved indications for ELIQUIS are based on a robust clinical trial programme1

ELIQUIS is available for your patients with NVAF1

ELIQUIS is available for your patients with
DVT / PE1


ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

DVT = Deep Vein Thrombosis   
NVAF = Non-Valvular Atrial Fibrillation   
PE = Pulmonary Embolism   
TF = Tissue Factor

References

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.
  2. Turpie AGG. Arterioscler Thromb Vasc Biol 2007; 27: 1238–1247.
  3. Eriksson BI et al. Annu Rev Med 2011; 62: 41–57.